Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review

Abstract EN

Mantle cell lymphoma (MCL) accounts for about 5% of all lymphomas.

Its clinical and histological features are heterogeneous.

After a frequently good initial response, the disease generally and repeatedly relapses and finally the outcome is poor.

Particularly severe is the prognosis of the rare occurrence of CNSi (Central Nervous System involvement).

Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), has shown strong activity in relapsing patients with Chronic Lymphocytic Leukemia (CLL) and MCL.

Few reports are available about treatment with ibrutinib of patients presenting CNSi by lymphoproliferative diseases (LPD).

In all of them, ibrutinib, at the dosage between 420 and 560 mg/day, showed an impressive effectiveness.

Here we describe a case of MCL with CNS relapse showing an excellent response to ibrutinib administered at the unusual dose of 280 mg/day because of concomitant treatment of cardiological disease.